Bliss GVS Pharma Limited — Others, 01-08-2025: Shareholders meeting

Bliss GVS Pharma shareholders have approved all resolutions at the 40th Annual General Meeting. Shareholders adopted the audited financial statements for the fiscal year ended March 31, 2025, and approved a final dividend of ₹0.50 per equity share. Dr. Vibha Gagan Sharma was re-appointed as a Director, and M/s. AVS & Associates were appointed as Secretarial Auditors. All proposals received overwhelming support from shareholders, reinforcing confidence in the company's governance and strategic direction.